Share This Page
Litigation Details for Fresenius Kabi USA, LLC v. Custopharm, Inc. (W.D. Tex. 2021)
✉ Email this page to a colleague
Fresenius Kabi USA, LLC v. Custopharm, Inc. (W.D. Tex. 2021)
| Docket | 1:21-cv-00164 | Date Filed | 2021-02-19 |
| Court | District Court, W.D. Texas | Date Terminated | 2021-03-23 |
| Cause | 35:271 Patent Infringement | Assigned To | Earl Leroy Yeakel III |
| Jury Demand | None | Referred To | |
| Patents | 10,398,669; 9,782,376 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Fresenius Kabi USA, LLC v. Custopharm, Inc.
Details for Fresenius Kabi USA, LLC v. Custopharm, Inc. (W.D. Tex. 2021)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2021-02-19 | External link to document | |||
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
Litigation summary and analysis for: Fresenius Kabi USA, LLC v. Custopharm, Inc. (W.D. Tex. 2021)
Fresenius Kabi USA, LLC v. Custopharm, Inc. (1:21-cv-00164) Litigation Summary and Patent/ANDA Exposure Analysis
Executive summary: Fresenius Kabi USA, LLC sued Custopharm, Inc. (case no. 1:21-cv-00164) alleging infringement of patents tied to an FDA-approved drug product in the Fresenius Kabi portfolio. The case is a typical Hatch-Waxman IP dispute track: the defendant’s ANDA/Paragraph IV certification and the plaintiff’s asserted Orange Book-listed patents drive the infringement theory. This matters commercially because the outcome controls generic market entry timing and licensing posture for the relevant dosage form and strength(s).
What this analysis covers: procedural posture, what the litigation generally means for generic entry risk, how courts typically assess infringement and invalidity in Paragraph IV cases, and what to watch for in settlement or final judgment events.
What patents were asserted in Fresenius Kabi USA, LLC v. Custopharm, Inc. (1:21-cv-00164)?
Featured snippet answer: The complaint identifies specific Orange Book patents tied to Fresenius Kabi’s FDA-approved product and asserts that Custopharm’s ANDA filings infringe one or more of those patents.
Key concept: In Hatch-Waxman cases, the asserted patent list is aligned to the Orange Book entry for the reference listed drug (RLD) and typically includes at least one of: formulation patents, method-of-use patents, and/or composition-of-matter patents, depending on the drug’s patent landscape.
How to interpret the asserted-patent set
Court filings typically reflect one of two patterns:
- Single-asset core patent(s): A small number of foundational patents (often composition/formulation) with broad claim coverage against the ANDA product.
- Layered estate: Multiple patents spanning different claim types, such as manufacturing or formulation parameters, plus method-of-use claims.
Business implication: A layered estate increases the chance of partial survival even if some patents fall on validity grounds. A single core patent increases reliance on infringement proof and claim construction outcomes.
What court events and procedural posture define the 1:21-cv-00164 timeline?
Featured snippet answer: Case numbering (1:21-cv-00164) indicates initiation in 2021. The litigation timeline in Paragraph IV disputes generally progresses through a fixed sequence: responsive pleadings, early claim construction and infringement/invalidity schedules, discovery, expert reports, and a Markman hearing followed by dispositive motions and trial or settlement.
Typical milestone stack in ANDA patent cases
While the precise docket entries for this specific case are not included in the prompt, the operational structure is consistent across district-court Hatch-Waxman dockets:
- Complaint filed: alleges infringement of Orange Book patents based on the ANDA submission.
- Answer and defenses: denial of infringement, affirmative invalidity and non-infringement defenses, and often procedural defenses related to notice and standing.
- Markman (claim construction): converts patent claims into legal meaning, often determinative for infringement.
- Summary judgment or trial: courts may decide invalidity/infringement on paper or after expert-driven trial.
- Final judgment or settlement: most cases resolve before final merits through settlement or consent judgment to avoid trial risk.
Business implication: For entry forecasting, the only docket events that change commercial outcomes materially are: entry of an injunction, dismissal with prejudice (if settlement), consent judgment terms, or a final invalidity ruling.
How strong is Fresenius Kabi’s patent estate in this dispute?
Featured snippet answer: Strength hinges on whether the asserted claims are (a) easy to map to the ANDA product (infringement), and (b) not vulnerable to established invalidity theories (anticipation/obviousness, written description/enablement, indefiniteness).
Strength signals plaintiffs usually show
Courts treat these as high-signal:
- Narrow ANDA product mapping: If claim limitations match manufacturing/formulation attributes that the ANDA must disclose or that can be proven through testing and process evidence, infringement is easier.
- Prior claim construction favorable to the patentee: If the court has construed key limitations in prior cases (same family/patent), that meaning can be reused.
- Commercially mature patent families: Later-expiring patents often include formulation or process improvements that can avoid earlier prior art.
Strength risks plaintiffs usually face
- High prior-art density: Especially for formulation/process patents where parameters could be taught by earlier literature.
- Indefiniteness or overbreadth: Courts reject claims that fail to inform boundaries, which can collapse infringement theories.
- Design-around space: If claim coverage allows generic substitutes outside the limitations.
Business implication: If Fresenius Kabi’s asserted patents include composition/formulation claims that are sensitive to formulation parameters (e.g., concentration, particle size, excipient ratios, pH ranges, osmolarity, sterility-related processes), the case becomes fact- and expert-heavy, raising settlement likelihood.
What generic entry risks does Custopharm face if patents are found invalid or non-infringed?
Featured snippet answer: If the court finds asserted patents invalid or not infringed, Custopharm’s ANDA can be eligible to launch immediately once statutory and regulatory conditions are satisfied.
Entry-risk pathways
- Full win for defendant: If all asserted patents are invalid or not infringed, Custopharm typically can enter without further delay from the asserted patent set.
- Partial win: If some patents survive, entry is often blocked or delayed until expiration of surviving patents, or the parties enter a license/settlement.
- Injunction: In typical Hatch-Waxman structures, if infringement is found and patents are valid, the court can prohibit FDA approval or prevent market launch as to those products until patent expiry (or until appeals resolve).
Business implication: Entry risk should be modeled by the number of surviving patents and their expiration dates. Even one surviving Orange Book patent can control timing.
Does this case include Paragraph IV certification and settlement dynamics?
Featured snippet answer: Paragraph IV certifications usually underlie this category of case and drive both infringement allegations and the 30-month stay risk.
What to expect procedurally under Paragraph IV
- The 30-month stay can delay FDA approval during litigation unless an earlier decision triggers earlier outcomes.
- Settlement often resolves by:
- a license with stated payment terms, or
- a covenant not to sue tied to a launch date, or
- consent judgments with defined noninfringement/nonassertion windows.
Business implication: The practical market effect is defined less by the general merits and more by whether the parties reached a consent judgment and what patents, strengths, and package sizes are covered.
What is the Orange Book status of Fresenius Kabi’s product in 1:21-cv-00164?
Featured snippet answer: The Orange Book status for the asserted patents is the central document connecting the FDA filing to the infringement claims.
How Orange Book listings map to case claims
For each asserted patent in the complaint, the typical Orange Book linkage includes:
- patent number
- patent expiration date
- patent type (e.g., drug substance, drug product, method of use)
- whether the patent is listed for specific strengths or dosage forms
Business implication: If the same patent family is listed across multiple strengths or package configurations, the scope of any enforcement or settlement commonly covers all linked listings unless the settlement is expressly limited.
Which claims typically survive claim construction in ANDA patent suits like this?
Featured snippet answer: Claims survive if their critical limitations are construed in a way that the accused ANDA product can be shown to meet, either structurally (composition/formulation) or functionally (method steps tied to use).
Common claim-construction pressure points
- Quantitative ranges: Courts require the ANDA product and process to meet numeric boundaries.
- Functional limitations: If a claim recites a performance parameter, the plaintiff must prove measurement methodology.
- Process steps: If the claim is manufacturing-related, the plaintiff must prove the process used by the generic.
Business implication: If Fresenius Kabi’s asserted claims depend on narrow numeric ranges or specific process steps, the case hinges on testing, batch records, and expert methodologies.
How does Fresenius Kabi’s litigation strategy typically affect outcomes in generic disputes?
Featured snippet answer: Plaintiffs typically focus on a small number of high-probability patents to maximize the chance of injunctive relief or leverage settlement.
Strategic behaviors observed across similar disputes
- Selecting patents with strong infringement mapping.
- Using expert testimony built around ORA (Office of Generic Drugs) and ANDA comparability standards.
- Targeting commercially meaningful strengths and package forms.
- Seeking early claim construction rulings to reduce uncertainty.
Business implication: When the asserted patent set is narrow and infringement is strongly supported, settlement can occur with defined launch dates. When asserted patents are broader but validity is fragile, plaintiffs may negotiate “pay-for-delay style” economics (depending on jurisdictional posture and settlements terms).
What patent litigation affects FDA approval and market entry in this matter?
Featured snippet answer: The litigated patents govern whether Custopharm can lawfully market the ANDA product; the legal outcome can trigger launch eligibility or further delay.
Regulatory and litigation interplay
- If patents are found invalid or not infringed, FDA approval and launch can proceed (subject to other statutory requirements).
- If patents are found infringed and valid, FDA approval may be limited by court orders or statutory framework, and launch can be blocked until patent expiry.
Business implication: Investors and commercial teams track the combination of (a) litigation outcome and (b) any FDA approval/labeling status that could allow market entry immediately after judicial resolution.
How does this dispute compare with other Fresenius Kabi vs. generic ANDA fights?
Featured snippet answer: Like most Fresenius Kabi generic-enforcement cases, the dispute is positioned as a patent estate gatekeeping exercise, with the plaintiff leveraging Orange Book-listed rights to delay generic entry or secure licensing.
Cross-case pattern
Across similar ANDA patent suits:
- the plaintiff cites Orange Book patents
- the defendant challenges invalidity and noninfringement
- settlements are common where claim construction or expert testimony creates uncertainty
Business implication: If Fresenius Kabi has a history of consistent settlements with defined launch dates, that increases the probability that the case resolves via consent judgment rather than trial.
Key Takeaways
- Case structure: This is a Hatch-Waxman type infringement action, meaning the asserted Orange Book patents and the ANDA Paragraph IV posture define the dispute.
- Commercial leverage: Outcomes typically determine whether Custopharm can launch immediately or must wait for patent expiry or a settlement license.
- Highest-impact docket events: Consent judgments, dismissal with prejudice, and final invalidity/infringement rulings drive entry timing.
- Patent estate quality matters most: The number of surviving patents and their expiration dates control residual launch risk even after partial defenses.
FAQs
- Do Paragraph IV settlements in ANDA cases typically include covenants not to sue, consent judgments, or licenses?
- Which claim types (composition, formulation, method-of-use) are most often decisive in ANDA infringement findings?
- How do courts treat expert testing and comparability data when proving infringement of formulation/process parameters?
- What litigation events trigger changes to the FDA 30-month stay in Hatch-Waxman cases?
- How do Orange Book patent listings by strength and dosage form affect settlement scope for generic launches?
References
No sources were provided in the prompt, and no case docket, complaint text, or Orange Book listings were included for this specific docket number. Therefore, no citations can be generated for this matter.
More… ↓
